Gene genie

17 January 2018 By Robert Cyran

The drug group may buy Juno Therapeutics, a biotech promising ways to modify immune cells to fight cancer. The two already have a partnership, but Celgene needs to grow. If it’s also sensing real potential, it could pay an eye-watering price for a firm with no approved products.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)